How our News is written
These articles are intended for ESMO members and for us it is vital that they are reliable and accurately reflect content from the original source and editorialists/commenters...
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
From the World Conference on Lung Cancer 2022:
Around a fifth of patients with thoracic cancer die within 30 days of COVID-19 infection but the risk is not predicted by recent receipt of systematic treatment for their malignancy
From the World Conference on Lung Cancer 2022:
Some participants of the KEYNOTE-604 trial with extensive-stage small-cell lung cancer have derived long-term survival benefits from the use of pembrolizumab plus etoposide
From the World Conference on Lung Cancer 2022:
NADIM II shows combining neoadjuvant chemotherapy with nivolumab before and after surgery improves progression-free and overall survival in resectable stage IIIA–B non-small-cell lung cancer
These articles are intended for ESMO members and for us it is vital that they are reliable and accurately reflect content from the original source and editorialists/commenters...
Receive a summary of latest published content every two weeks.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.